Overview
TEVA market data
Price History
TEVA price chart
Valuation & Profitability
- P/E (TTM)
- 25.52 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.21 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.58 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5,305.00 – $11,350.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $123K · P/B 4.75 · P/S 2.31.
Company News
Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE ListingBenzinga · Jul 29, 2026, 5:56 PM
Teva Pharmaceutical shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance with its midpoint above estimates.Benzinga · Jul 29, 2026, 11:52 AM
Teva Pharmaceutical Indus Lowers FY2026 Adj EPS Guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 Est; Raises FY2026 Sales Guidance from $16.400B-$16.800B to $16.500B-$16.850B vs $16.618B EstBenzinga · Jul 29, 2026, 11:20 AM
Teva Announces Replacement Of ADS Program With Direct NYSE Listing Of Ordinary Shares On One-For-One Basis; Trading Begins September 14, 2026Benzinga · Jul 29, 2026, 11:12 AM
Teva Pharmaceutical Indus Q2 Adj. EPS $0.02 Misses $0.25 Estimate, Sales $4.142B Beat $4.047B EstimateBenzinga · Jul 29, 2026, 11:00 AM
Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $44Benzinga · Jul 28, 2026, 3:00 PM
Shares of generic drug companies are trading lower after President Trump announced that imported generics will be subject to a 100% import tariff following a two-year grace period in order to encourage reshoring of pharma manufacturing.Benzinga · Jul 22, 2026, 4:27 PM
U.S. Appeals Court Revives Teva Pharmaceuticals' Lawsuit Against Eli Lilly Over Alleged Violation Of Settlement AgreementBenzinga · Jul 13, 2026, 7:30 PM
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?The Motley Fool · Jul 9, 2026, 5:15 PM
Teva Pharmaceuticals International Granted Exclusive Rights To Commercialize Formulations For Polpharma Biologics’ Proposed Biosimilar To OcrevusBenzinga · Jul 9, 2026, 12:50 PM